Back to funds
View filing
Deep Track Capital, LP
hedge fundUpdated 27 days agoManaged by Deep Track Capital, Lp • Latest filing Q2 2026
Portfolio value
$6.9B
Q2 2026
Filings
14
Quarterly 13F history
Top-10 concentration
98.8%
Weight of largest holdings
Annualized return
—
Implied from 13F holdings
Portfolio value history
13F-disclosed portfolio value over 14 quarters
Show data table
| Period | Portfolio value |
|---|---|
| Q1 2023 | $2.4B |
| Q2 2023 | $2.2B |
| Q3 2023 | $2.6B |
| Q4 2023 | $3B |
| Q1 2024 | $3.5B |
| Q2 2024 | $3.4B |
| Q3 2024 | $3.2B |
| Q4 2024 | $2.7B |
| Q1 2025 | $3.1B |
| Q2 2025 | $3.1B |
| Q3 2025 | $3.6B |
| Q4 2025 | $5.6B |
| Q1 2026 | $6.1B |
| Q2 2026 | $6.9B |
Top holdings
67 positions as of Q2 2026
| # | Stock | Value | Shares | % Portfolio | Change |
|---|---|---|---|---|---|
| 1 | G GH GUARDANT HEALTH INC | $509.1M | 3.39M | 7.41% | — |
| 2 | I IMVT IMMUNOVANT INC | $359.9M | 9.34M | 5.24% | — |
| 3 | G GPCR STRUCTURE THERAPEUTICS INC | $254.4M | 4.74M | 3.70% | — |
| 4 | P PCVX VAXCYTE INC | $250M | 4.30M | 3.64% | — |
| 5 | A ALNY ALNYLAM PHARMACEUTICALS INC | $248.3M | 825.0K | 3.61% | — |
| 6 | M MANE VERADERMICS INC | $245.9M | 2.00M | 3.58% | — |
| 7 | T TARS TARSUS PHARMACEUTICALS INC | $230.8M | 3.67M | 3.36% | — |
| 8 | ? N/A NUVALENT INC | $220.2M | 1.78M | 3.21% | — |
| 9 | A ALKS ALKERMES PLC | $209.6M | 4.00M | 3.05% | — |
| 10 | O OCFC OCULAR THERAPEUTIX INC | $193.3M | 19.69M | 2.81% | — |
| 11 | B BMRN BIOMARIN PHARMACEUTICAL INC | $189.3M | 3.31M | 2.75% | — |
| 12 | N NRIX NURIX THERAPEUTICS INC | $187.7M | 7.74M | 2.73% | — |
| 13 | O ORKA ORUKA THERAPEUTICS INC | $183.3M | 1.93M | 2.67% | — |
| 14 | A ALMS ALUMIS INC | $178.6M | 6.35M | 2.60% | — |
| 15 | I IONS IONIS PHARMACEUTICALS INC | $174.4M | 2.20M | 2.54% | — |
| 16 | C CMPS COMPASS PATHWAYS PLC | $172.1M | 12.16M | 2.50% | — |
| 17 | V VERA VERA THERAPEUTICS INC | $171.6M | 4.00M | 2.50% | — |
| 18 | A AXSM AXSOME THERAPEUTICS INC. | $171.3M | 700.0K | 2.49% | — |
| 19 | G GNMSF GENMAB A/S | $155.2M | 5.65M | 2.26% | — |
| 20 | M MLTX MOONLAKE IMMUNOTHERAPEUTICS | $136.3M | 7.00M | 1.98% | — |